Switching to a Second TNF-α Inhibitor in a Patient with Severe Juvenile Polyarthritis: A Clinical Case

Switching to a Second TNF-α Inhibitor in a Patient with Severe Juvenile Polyarthritis: A Clinical Case

Background. Insufficient efficacy or intolerance of the first TNF-α inhibitor in patients with juvenile idiopathic arthritis (JIA) is an indication for the appointment of a second inhibitor. Golimumab is a new TNF-α inhibitor registered for treating JIA under pediatric indications. Clinical Case Des...

ver descrição completa

Detalhes bibliográficos
Principais autores: Ekaterina V. Denisova, Ekaterina I. Alexeeva, Tatyana M. Dvoryakovskaya, Margarita A. Soloshenko, Anna V. Mamutova, Kseniya B. Isayeva, Anna N. Fetisova
Formato: Artigo
Idioma:English
Publicado em: "Paediatrician" Publishers LLC 2018-10-01
coleção:Вопросы современной педиатрии
Assuntos:
children
juvenile idiopathic arthritis
genetically engineered biological preparations
golimumab
infliximab
Acesso em linha:https://vsp.spr-journal.ru/jour/article/view/1931

Internet

https://vsp.spr-journal.ru/jour/article/view/1931

Registros relacionados